Galapagos, Prolysis extend antibiotic resistance research collaboration

By Angela McDaniels

Seattle, Dec. 30 - Galapagos NV and Prolysis Ltd. said they have extended a research collaboration under which Galapagos' services division BioFocus plc is working to identify dual enzyme inhibitors that can overcome antibiotic resistance.

The collaboration began earlier this year, and Prolysis will continue to fund the research through the end of 2006. Prolysis also has the option to access in vitro ADMET and computational chemistry services from BioFocus during this period.

"Progress made in the collaboration with Prolysis indicates how BioFocus' drug discovery services can accelerate a development program," Galapagos chief executive officer Onno van de Stolpe said in a company news release.

Prolysis is a research and development company based in Oxford, England, that creates medicines that address antibiotic resistance.

Galapagos is a drug discovery company headquartered in Mechelen, Belgium. It provides target-to-drug discovery products and services to pharmaceutical and biotechnology companies through its BioFocus division.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.